Alphina Therapeutics is redefining precision oncology by developing antibody-drug conjugates (ADCs) with a novel mechanism of action – NAMPT inhibition. We have unlocked the potential of NAMPT with an optimized linker-payload and a patient selection strategy that identifies the tumors most sensitive to our payload. Our mission is to apply these breakthroughs to deliver smarter, more effective cancer therapies to the patients who urgently need them.